These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24566512)

  • 1. Cognitive subdomain responses to galantamine in Alzheimer's disease.
    Song J; Ahn IS; Kang HS; Myung W; Lee Y; Woo SY; Ku HM; Hwang TY; Carroll BJ; Kim DK
    J Nerv Ment Dis; 2014 Mar; 202(3):253-9. PubMed ID: 24566512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.
    Thavichachart N; Phanthumchinda K; Chankrachang S; Praditsuwan R; Nidhinandana S; Senanarong V; Poungvarin N
    Int J Clin Pract; 2006 May; 60(5):533-40. PubMed ID: 16700849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galantamine treatment of vascular dementia: a randomized trial.
    Auchus AP; Brashear HR; Salloway S; Korczyn AD; De Deyn PP; Gassmann-Mayer C;
    Neurology; 2007 Jul; 69(5):448-58. PubMed ID: 17664404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
    Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
    J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
    Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
    Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors.
    Rockwood K; Howlett SE; Hoffman D; Schindler R; Mitnitski A
    Alzheimers Dement; 2017 Oct; 13(10):1098-1106. PubMed ID: 28341540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.
    Rockwood K; Fay S; Gorman M
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
    Rockwood K; Dai D; Mitnitski A
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
    Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
    J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months.
    Wilkinson DG; Hock C; Farlow M; van Baelen B; Schwalen S
    Int J Clin Pract; 2002 Sep; 56(7):509-14. PubMed ID: 12296613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.
    Oka M; Nakaaki S; Negi A; Miyata J; Nakagawa A; Hirono N; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):121-34. PubMed ID: 26114924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two galantamine titration regimens in patients switched from donepezil.
    Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
    Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.
    Rockwood K; Fay S; Song X; MacKnight C; Gorman M;
    CMAJ; 2006 Apr; 174(8):1099-105. PubMed ID: 16554498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.
    Bullock R; Erkinjuntti T; Lilienfeld S;
    Dement Geriatr Cogn Disord; 2004; 17(1-2):29-34. PubMed ID: 14560062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galantamine treatment in outpatients with mild Alzheimer's disease.
    Richarz U; Gaudig M; Rettig K; Schauble B
    Acta Neurol Scand; 2014 Jun; 129(6):382-92. PubMed ID: 24461047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
    Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
    J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease.
    Wilkinson D; Murray J
    Int J Geriatr Psychiatry; 2001 Sep; 16(9):852-7. PubMed ID: 11571763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.